Ascomycins: promising agents for the treatment of inflammatory skin diseases

Bibliography

• ��of considerable interest
   Google Scholar
• FINLAY AY: Quality of life issues and economic burden of psoriasis and atopic dermatitis. Rational for treatment. Clin. Drug Invest. (1995) 10\(Suppl. 0:1–6.
   Google Scholar
• STERN RS: Epidemiology of psoriasis. Dermatol Clin. (1995) 13:717–722.
   PubMed Web of Science ®Google Scholar
• WILLIAMS HC: Atopic dermatitis. In: The Challenge Of Dermato-Epidemiology. Williams HC, Strachan DP (Eds.) CRC Press, New York, USA (1997):125–144.
   Google Scholar
• KLIGMAN AM, FROSCH PJ: Steroid addiction. Int. J.Dermatol. (1979) 18:23-31.29.
   Google Scholar
• FISHER DA: Adverse effects of topical corticosteroids use. West. J. Med. (1995) 162:123–126.
   PubMedGoogle Scholar
• FEIWEL M et al: Adrenal unresponsiveness associated with clobetasol propionate. Lancet (1974) 2:112–113.
   PubMed Web of Science ®Google Scholar
• WESTON WL et al.: Morning plasma cortisol levels in infants treated with topical fluorinated glucocorticos-teroids. Pediatrics. (1980) 65:103–106.
   PubMed Web of Science ®Google Scholar
• BODE HH: Dwarfism following long-term topical corticosteroid therapy. JAMA (1980) 244:813–814.
   PubMed Web of Science ®Google Scholar
• DRAKE L, DINEHART SM, FARMER ER eta].: Guidelines of care for the use of topical glucocorticosteroids. J. Am. Acad. Dermatol. (1996) 35:615–619.
   PubMed Web of Science ®Google Scholar
• GRASSBERGER M, MEINGASSNER J et al.: Ascomycins. In: Psoriasis 3rd Edition. Roenigk H, Maibach H (Eds.) Marcel Decker, Inc., (1998) 66:9769–9779.
   Google Scholar
• STUETZ A., GRASSBERGER M., BAUMANN K. et al: Immunophilins as drug targets. In: Perspectives in Medicinal Chemistry. Testa B, Kyburz E (Eds.), Verl. Helvetica Chimica Acta, Verlag Chemie, Basel (1993):427–433.
   Google Scholar
• ARAI T, KOYAMA Y, SUENAGA T et al: Ascomycin, an antifimgal antibiotic. J AntibioL Ser. (1962) 15:231–232.
   PubMed Web of Science ®Google Scholar
• HATANAKA H, KINO T, MIYATA S et al.: FR-900520 and FR-900523, novel immunosuppressants isolated from a Streptomyces II. Fermentation, isolation and physico-chemical and biological characteristics. J. Antibiot. (1988) 41:1592–1601.
   Google Scholar
• MEINGASSNER J, STUETZ A: Anti-inflammatory effects of macrophilin-interacting drugs in animal models of irritant and allergic contact dermatitis. Inter. Arch. Allergy Immunol (1992) 99:486–489.
   PubMed Web of Science ®Google Scholar
• RAPPERSBERGER K, MEINGASSNER JG, FIALLA R et al.: Clearing of psoriasis by a novel immunosuppressive macrolide. J. Invest. Dermatol. (1996) 106:701–710.
   PubMed Web of Science ®Google Scholar
• VAN LEENT EJM, GRAEBER M, THURSTON M et al.: Effectiveness of the ascomycin macrolactam SDZ ASM 981 in the topical treatment of atopic dermatitis. Arch. Dermatol. (1998) 134:805–809.
   PubMed Web of Science ®Google Scholar
• GRASSBERGER M, BAUMRUKER T et al.: A novel anti-inflammatory drug, SDZ ASM 981, for the treatment of skin disease: in vitro pharmacology. Br. J. Dermatol. (1999) 141:264–273.
   PubMed Web of Science ®Google Scholar
• MOLLISON KW: Discovery of ascomycin analogs withpotent topical but weak systemic activity for the treatment of inflammatory skin diseases. Curr. Pharm. Des. (1998) 4:367–379.
   PubMed Web of Science ®Google Scholar
• DARSOW U, VIELUF D, RING J: Evaluating the relevanceof aeroallergen sensitization in atopic eczema with the atopy patch test: a randomized, double-blind multicenter study. Atopy patch test study group. J. Am. Acad. Dermatol. (1999) 40:187–193.
   PubMed Web of Science ®Google Scholar
• RUZICKA T, BIEBER T et al. A short term trial oftacrolimus ointment for atopic dermatitis. N Engl. J. Med. (1997) 337:816–821.
   PubMed Web of Science ®Google Scholar
• HULTSCH T, MUELLER KD, MEINGASSNER JG, GRASSBERGER M, SCHOPF RE, KNOP J: Ascomycin macrolactam derivative SDZ ASM 981 inhibits the release of granule-associated mediators and of newly synthesized cytokines in RBL 2113 mast cells in an immunophilin-dependent manner. Arch. Dermatol. Res. (1998) 290:501–507.
   PubMed Web of Science ®Google Scholar
• MEINGASSNER JG, GRASSBERGER M, FAHRNGRUBER H etal.: A novel anti-inflammatory drug, SDZ ASM 981, for the topical and oral treatment of skin diseases: in vivo pharmacology. Br. J. Dermatol (1997) 137:568–576.
   Google Scholar
• SAURAT JH, CHAVAZ P, PONVERT C, GALLOPIN L. Skininflammation induced by hypomagnesaemia in the rat. Br. J. Dermatol. (1983) 109:106–110.
   PubMed Web of Science ®Google Scholar
• NECKERMANN G., BAVANDI A, MEINGASSNER JG. OralSDZ ASM 981 inhibits pruritic erythematous rash in hypomagnesesmic hairless rats. J. Invest. Dermatol (1998) 110:682.
   Web of Science ®Google Scholar
• KOIVUKANGAS V, KARVONEN J, RISTELI J et al: Topicalmometasone furoate and betamethasone-17-valerate decrease collagen synthesis to a similar extent in human skin in vivo. Br. J. Dermatol. (1995) 132:66–68.
   PubMed Web of Science ®Google Scholar
• HAAPASAARI KM, RISTELI J, KARVONEN J et al: Effect ofhydrocortisone methylprednisolone aceponate and momethasone furoate on collagen synthesis in human skin in vivo. Skin Pharmacol. (1997) 10:261–264.
   PubMedGoogle Scholar
• NICKOLOFF BJ: The immunologic and genetic basis ofpsoriasis. Arch Dermatol. (1999) 135:1104–1110.
   PubMed Web of Science ®Google Scholar
• MROWIETZ U, BRAEUTIGAM M, GRAEBER M et al.: Thenovel ascomycin derivative SDZ ASM 981 is effective for psoriasis when used topically under occlusion. Br. Dermatol. (1998) 139:992-996. BOS, JD, KAPSENBERG ML, SILLEVIS SMITT JH: Pathogenesis of atopic eczema. Lancet. (1994) 343:1338–1341.
   Google Scholar
• LEUNG DYM: Atopic dermatitis: immunobiology and treatment with immune modulators. Clin. Exp. Immunol. (1997) 107(Suppl.):25–30.
   Google Scholar
• GRAEBER M, VAN LEENT EJM, BURTIN P et al.: Profiling SDZ ASM 981: evaluation of local tolerability and safety in the treatment of atopic dermatitis. Ann. Dermatol Venereol (1998) 125\(Suppl. 0:214–215.
   Google Scholar
• KAWASHIMA M: Tacrolimus concentrations in blood during topical treatment of atopic dermatitis. Lancet (1996) 348:1240–1241.
   PubMed Web of Science ®Google Scholar
• JAPANESE FK506 STUDY GROUP: Long-term study of FK506 (tacrolimus) ointment in patients with atopic dermatitis. Rinsho Iyaku (1998) 14:2405–2432.
   Google Scholar
• VAN LEENT EJM, GRAEBER M, EBELIN ME et al.: Efficacyand safety of SDZ ASM 981 cream in atopic dermatitis. J. Eur. Acad. Dermatol. Venereol (1999) 12 (Suppl. 2):51.
   Google Scholar
• TURPEINEN M, SALO OP, LEISTI S: Effect of hydrocorti-sone on adrenocorticol responsiveness in infants with severe skin diseases. Br. J. Dermatol. (1986) 115:475–484.
   PubMed Web of Science ®Google Scholar
• HARPER J, GREEN A, EBELIN ME, SCOTT G, BURTIN P:Low systemic SDZ ASM 981 concentrations in children 1–4 years old treated with the 1% cream for their atopic dermatitis. J. Eur. Acad. Dermatol. (1999) 12 (Suppl. 2):159.
   Google Scholar
• MORRIS A, CARDNO M, BURTIN P, SCOTT G, EBELIN ME,ALLEN R.: Low systemic SDZ ASM 981 exposure in children 5–16 years old treated with the 1% cream for their atopic dermatitis. J. Eur. Acad. Dermatol. (1999) 12 (Suppl. 2):160.
   Google Scholar
• KAIDBEY KH, KLIGMAN AM: Assay of topical corticos-teroids. Efficacy of suppression of experimental Rhus dermatitis in humans. Arch. Dermatol. (1976) 112:808–810.
   PubMedGoogle Scholar
• QUEILLE-ROUSSEL C, DUTEIL L, PADILLA JM, PONCET M, CZERNIELEWSKI J: Objective assessment of topical anti-inflammatory drug activity on experimentally induced nickel contact dermatitis: comparison between visual scoring, colorimetry, laser doppler velocimetry and transepidermal water loss. Skin Pharmacol. (1990) 3:248–255.
   PubMedGoogle Scholar
• QUEILLE-ROUSSEL C, GRAEBER M, THURSTON M et al.: Topical treatment with the anti-inflammatory macrolactam SDZ ASM 981 inhibits established nickel contact dermatitis. Austral. J. Dermatol. (1997) 38 (Suppl. 2):234.
   Google Scholar
• QUEILLE-ROUSSEL C, PAUL C, DUTEIL L et al: A random-ised, double.blind, controlled study on the atropho-genic potential of SDZ ASM 981.1 Eur. Acad. Dermatol (1999) 12 (Suppl. 2):350.
   Google Scholar